Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADI-PEG20 plus FOLFOX in previously treated advanced hepatocellular carcinoma
CTR20182490Phase 2Suspended
- Sponsor
- Polaris Group
- Start
- Jan 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of Pegargiminase in hepatocellular carcinoma (HCC), sponsored by Polaris Group. Started Jan 2019; status: suspended.
02
Drugs
Pegargiminase
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20182490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20182490.